Efficacy and durability of multifactorial intervention on mortality and MACEs:a randomized clinical trial in type-2 diabetic kidney disease by NID-2 Study Group Investigators et al.
Sasso et al. Cardiovasc Diabetol          (2021) 20:145  
https://doi.org/10.1186/s12933-021-01343-1
ORIGINAL INVESTIGATION
Efficacy and durability of multifactorial 
intervention on mortality and MACEs: 
a randomized clinical trial in type-2 diabetic 
kidney disease
Ferdinando Carlo Sasso1* , Pia Clara Pafundi1, Vittorio Simeon2, Luca De Nicola1, Paolo Chiodini2, 
Raffaele Galiero1, Luca Rinaldi1, Riccardo Nevola1, Teresa Salvatore3, Celestino Sardu1, Raffaele Marfella1, 
Luigi Elio Adinolfi1 and Roberto Minutolo1 on behalf of NID-2 Study Group Investigators 
Abstract 
Background: Multiple modifiable risk factors for late complications in patients with diabetic kidney disease (DKD), 
including hyperglycemia, hypertension and dyslipidemia, increase the risk of a poor outcome. DKD is associated with 
a very high cardiovascular risk, which requires simultaneous treatment of these risk factors by implementing an inten-
sified multifactorial treatment approach. However, the efficacy of a multifactorial intervention on major fatal/non-fatal 
cardiovascular events (MACEs) in DKD patients has been poorly investigated.
Methods: Nephropathy in Diabetes type 2 (NID-2) study is a multicentre, cluster-randomized, open-label clinical 
trial enrolling 395 DKD patients with albuminuria, diabetic retinopathy (DR) and negative history of CV events in 14 
Italian diabetology clinics. Centres were randomly assigned to either Standard-of-Care (SoC) (n = 188) or multifactorial 
intensive therapy (MT, n = 207) of main cardiovascular risk factors (blood pressure < 130/80 mmHg, glycated haemo-
globin < 7%, LDL, HDL and total cholesterol < 100 mg/dL, > 40/50 mg/dL for men/women and < 175 mg/dL, respec-
tively). Primary endpoint was MACEs occurrence by end of follow-up phase. Secondary endpoints included single 
components of primary endpoint and all-cause death.
Results: At the end of intervention period (median 3.84 and 3.40 years in MT and SoC group, respectively), targets 
achievement was significantly higher in MT. During 13.0 years (IQR 12.4–13.3) of follow-up, 262 MACEs were recorded 
(116 in MT vs. 146 in SoC). The adjusted Cox shared-frailty model demonstrated 53% lower risk of MACEs in MT arm 
(adjusted HR 0.47, 95%CI 0.30–0.74, P = 0.001). Similarly, all-cause death risk was 47% lower (adjusted HR 0.53, 95%CI 
0.29–0.93, P = 0.027).
Conclusion: MT induces a remarkable benefit on the risk of MACEs and mortality in high-risk DKD patients.
Clinical Trial Registration ClinicalTrials.gov number, NCT00535925. https:// clini caltr ials. gov/ ct2/ show/ NCT00 535925
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Background
Type 2 diabetes mellitus (T2DM) patients are at high risk 
of death, myocardial infarction (MI) and stroke com-
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onset of diabetic kidney disease (DKD) remarkably wors-
ens cardiovascular prognosis, as demonstrated by a very 
large meta-analysis showing that hazards for cardiovas-
cular mortality at a given eGFR/albuminuria are higher 
among T2DM patients throughout the whole spectrum 
of disease [2]. The major role of DKD on cardiovascular 
outcome has also been supported by an observational 
study on 1.3 million of patients reporting a higher inci-
dence rate of MI in DKD patients versus diabetes or 
chronic kidney disease alone [3]. Of note, this finding is 
enhanced by the coexistence of proteinuria; indeed, albu-
minuria and low eGFR per se accelerate atherosclerosis 
process. Such a marked cardiovascular risk significantly 
modifies the outcome of DKD patients who often do not 
survive long enough to reach the natural fate of end-stage 
kidney disease [3–6].
The importance of a multifactorial approach in T2DM 
has been emphasized by the analysis of Swedish National 
Diabetes Register comparing prognosis of ~ 270,000 
T2DM patients versus ~ 1,300,000 age- and gender-
matched controls [1]. In particular, T2DM patients with 
five risk-factors within target range showed either a 
small or any excess risk of death, MI or stroke, as com-
pared with controls [1]. However, DKD was either mild 
or absent in the vast majority of patients (mean GFR 
84  mL/min and 4.9% with macroalbuminuria). Further-
more, achievement of targets for multiple risk factors was 
uncommon (5%).
As for observational studies, also multi-target interven-
tional trials in DKD are lacking. The Steno-2 is the only 
study evaluating the effects of multifactorial approach 
in 160 microalbuminuric patients. The trial disclosed a 
significant reduction of both mortality and cardiovas-
cular risk after implementing an intensified approach to 
multiple targets [7, 8]. However, Steno-2 was a single-
centre study, carried out in patients with preserved renal 
function (mean GFR 118  mL/min) and mostly without 
diabetic retinopathy (DR) (74%), that is, a sign of micro-
angiopathy strictly associated with cardiovascular risk 
besides being a recognized marker of DKD [9].
Aim of the present trial is to evaluate the efficacy of a 
multifactorial intensive therapy (MT) versus Standard-
of-Care (SoC) on major fatal and non-fatal cardiovascu-
lar events (MACEs) in a population with DKD patients 
with albuminuria and retinopathy. Durability of the effect 
of intensified treatment was tested by extending follow-
up to several years after the end of intervention phase.
Methods
Trial design
The Nephropathy In Diabetes type 2 (NID-2) study is an 
open-label cluster randomized clinical trial in a popula-
tion referred to 14 Italian diabetology clinics [10]. To 
maximize the contrast between the two approaches, we 
randomized clinics rather than patients. Indeed, in the 
latter modality of randomization similarities between 
the two interventions are expected to ensue over the 
long-term. Centres were randomly assigned to either MT 
therapy or SoC. A questionnaire ascertained that all par-
ticipating physicians were well aware of the guidelines on 
T2DM management published at the time of the study 
[11–14].
All MACEs diagnoses were performed in each patient 
according to the diagnostic criteria defined by the inter-
national standards of care guidelines [15–17]. MACEs 
were evaluated by cardiologist blinded to the study arm 
(MT or SoC), either belonging to the same Centres or to 
hospitals where patients were referred for acute events.
Participants and procedures
We considered eligible T2DM patients with age 
≥40 years, persistent albuminuria ≥30 mg/24 h in at least 
two of three 24 h-urine collections in the last 6 months), 
severe DR (according to the Wilkinson et al.) [18], diabe-
tes onset at age > 30 years, absence of neoplastic/psychi-
atric diseases and follow-up at the centre ≥ 12  months. 
Exclusion criteria were previous MI or stroke, severe 
hepatic or cardiac failure.
Patients were enrolled between October 2005 and 
October 2008. The intervention phase was scheduled for 
a period of four years, and it was completed in Decem-
ber 2011. Then, patients were followed until May 2019 
to achieve the number of events needed for the primary 
outcome.
The protocol was approved by the ethics committee of 
University of Campania “Luigi Vanvitelli” (clinicaltrials.
gov: NCT00535925) and is in accordance with the 1976 
Declaration of Helsinki and its later amendments. All 
participants signed their informed consent.
Randomization
All patients enrolled in each clinic were randomized, 
according to a cluster-randomization procedure, in two 
arms, MT and SoC. Randomization of centres was strati-
fied based on their size, in order to reduce difference in 
the number of patients allocated to the two treatment 
arms.
The intensified therapy group was initiated to the ther-
apeutic regimen summarized below and detailed and in 
Additional file  1: Appendix S1. Patients assigned to the 
conventional therapy group followed the therapy usually 
administered at their outpatient clinic; hence, they could 
receive any therapeutic change considered appropriate 
by their caregiver, under the respect of the good clinical 
practice rules.
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Targets
In either arm participating physicians were required 
to adhere to guideline-based clinical targets recom-
mended at the time of study initiation: [11–14] (a) 
systolic blood pressure (SBP) < 130  mmHg, (b) dias-
tolic blood pressure (DBP) < 80  mmHg, (c) glycated 
haemoglobin (HbA1c) < 7%, (d) fasting serum LDL 
cholesterol < 100  mg/dL, (e) fasting serum HDL choles-
terol > 40/50  mg/dL (for men/women, respectively), and 
(f ) fasting total serum cholesterol < 175 mg/dL.
Study arms
In SoC group, the subjects received the therapy usually 
administered at their diabetic outpatient for the manage-
ment of blood pressure, glycaemic and lipid control, and 
antiplatelet treatment. During the study, these patients 
received all therapeutic modifications considered appro-
priate by their physician, in the respect of the good clini-
cal practice.
In MT group, the patients were treated with pre-
specified algorithm for management of hypertension, 
glycol-metabolic control and dyslipidemia, including 
non-pharmacological and pharmacological treatment, as 
detailed in Additional file 1: Appendix 1. Briefly, specific 
recommendation for physical activity and low sodium 
diet were provided to patients in written form. In addi-
tion, renin–angiotensin system blockade was imple-
mented by initial association of ACEi and ARBs with a 
strict monitoring of GFR and serum potassium, followed 
by stepwise addition of other anti-hypertensive drug 
classes. They received low-dose aspirin as primary pre-
vention, unless contraindicated or not tolerated. Statin 
was added if non-pharmacological therapy was ineffec-
tive in reaching the target.
All patients, regardless of the study group, under-
went control visits at their diabetes centre every six 
months to monitor laboratory and clinical parameters 
and compliance to therapies and lifestyle hints. During 
each visit, investigators carefully monitored the occur-
rence of adverse events. In MT group, additional vis-
its could be planned if one or more risk factors resulted 
out of target. At each visit, adherence to pharmacologi-
cal protocol as well as to lifestyle recommendations (see 
Additional file  1: Appendix S1) was strictly monitored 
and strengthened.
eGFR was estimated using the CKD-EPI equation and, 
since creatinine was not standardized, we reduced creati-
nine values by 5% [19].
Outcomes
Primary endpoint was a composite of fatal and non-fatal 
MACEs, including cardiovascular mortality, non-fatal MI 
(documented instrumentally and/or enzymatically), non-
fatal stroke, coronary-artery by-pass, revascularization 
procedures (PTCA) and lower limbs major amputation, 
whichever occurred first. In both arms, all endpoints 
were captured and recorded by investigators in an elec-
tronic Case Report Form (CRF) at each visit.
Since the planned number of events was not reached 
during the initial 4-year time frame (interventional 
phase), incidence of the primary end point was assessed 
throughout the follow-up phase, that in the original study 
design was planned to assess the durability of effects of 
the intensified treatment.
During this extension phase, following the end of inter-
vention, all patients enrolled in both arms were treated 
by their own physicians according to the good clinical 
practice.
As secondary endpoints, we considered each single 
component of primary endpoint, and all-cause death at 
the end of the follow-up phase, as well as MACEs and the 
achievement of BP, HbA1c and total, HDL and LDL cho-
lesterol goals at the end of intervention phase.
Sample size
Study is powered to detect a Hazard Ratio (HR) of 0.67 
in the comparison of the two groups, with an 80% power 
and a two-sided type I error of 5%, assuming an intraclass 
correlation coefficient of 0.01. For this purpose, with a 
sample size of about 420 patients, 14 overall clusters, an 
average of 30 subjects per cluster, and an expected sur-
viving proportion of 30% at ten years in the SoC group, 
we determined a number of events needed of 258.
Statistical analysis
All statistical analyses were performed after the end of 
the follow-up and the achievement of number of events 
needed for the analysis of the primary outcome. A sta-
tistical analysis plan was prepared before the central 
database was locked for final data extraction and analy-
sis. Categorical data were expressed as number and per-
centage, while continuous variables as either median 
and interquartile range or mean and standard deviation, 
based on their distribution assessed by the Shapiro–Wilk 
test. In order to check for imbalance in cluster rand-
omization, we compared variables at baseline by using 
the method proposed by Leyrat et  al. [20] Standardized 
differences (SDiff) were calculated for continuous and 
dichotomous variable. P-values to take into account clus-
tering were computed by generalized estimating equa-
tions (GEE) model with cluster as group variable [21]. 
Distribution of dependent variable and link function 
was used as appropriate (gaussian and identity for con-
tinuous variable, binomial and logit for dichotomous 
variable). Comparison of groups at end of intervention 
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was performed applying the same methodology, further 
adjusting for baseline values as covariate.
Criteria on SDiff cut-offs reported by Leyrat et al. [20] 
were used to establish covariates imbalanced at baseline. 
Moreover, to evaluate a global imbalance, c-statistic was 
calculated performing a logistic model with treatment 
arm as dependent variable and selected baseline variables 
as covariate.
Median follow-up time was calculated by the inverse 
Kaplan–Meier procedure. The primary endpoint was 
analysed according to the intention-to-treat principle, 
with event curves for the time-to-first event based on 
Kaplan–Meier analysis. Cox regression model was used 
to calculate HR and 95% Confidence Interval (CI). Due 
to the cluster randomized study design, a Cox shared-
frailty model was fitted. Across centres, the frailties are 
assumed to be gamma-distributed latent random effects 
affecting the hazard multiplicatively. In the univariate 
analysis, only treatment group was included as covariate. 
In the multivariable analyses, depending on imbalance 
detection of each variable (Leyrat method), associa-
tion with the outcome of interest and evidence from the 
literature, we adjusted the Cox regression models for age, 
sex, SBP, haemoglobin, eGFR, albuminuria, HbA1c, total 
cholesterol, triglycerides (log-scaled), statins and anti-
platelets therapy at baseline to reduce risk of bias. Data 
were analysed using STATA 16.0 software (StataCorp. 
2019. College Station, TX: StataCorp LLC).
Results
Patients
Out of the 850 eligible patients originally enrolled in 
the NID2 cross-sectional study [10, 22], we randomized 
395 patients (207 to MT arm and 188 to SoC arm). Flow 
chart is reported in Fig. 1. Intervention and SoC groups 
were mostly similar for baseline characteristics (Table 1). 
However, patients in the group SoC were slightly older 
than those randomized to MT arm. HbA1c goal was 
more prevalent among controls. All variables, except for 
creatinine, showed a value of SDiff higher than 5%. These 
values are reported in Additional file  2: Fig. S1 to pro-
vide information on the direction (treatment arm) of the 
imbalance. Overall, SoC arm showed a more favourable 
baseline clinical picture compared with the intervention 
Fig. 1 Flow chart of patients participating to the study
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Table 1 Baseline characteristics of the study population (n = 395)
Parameter SoC (n = 188) Intervention (n = 207) p SDiff (%)
Male Sex, No. (%) 83(44.1) 103 (49.8) 0.382 11.3
Age, mean (SD), y 68.2 (8.8) 66.1 (9) 0.046 24.1
BMI (kg/m2), mean (SD) 29.4 (4.9) 28.5 (4.7) 0.288 19.1
Blood pressure (mmHg), mean (SD)
 Systolic 134.7 (12.6) 133.8 (14.3) 0.791 6.1
 Diastolic 78.3 (7.7) 80.8 (7.4) 0.002 − 32.8
Systolic BP target, No. (%) 95 (50.5) 112 (54.1) 0.142 − 17.0
Diastolic BP target, No. (%) 150 (79.8) 136 (65.7) 0.274 19.2
Blood Pressure Target, No. (%) 90 (47.9) 105 (55.3) 0.193 − 14.8
Creatinine (mg/dL), mean (SD) 1.16 (0.5) 1.17 (0.5) 0.564 − 1.4
eGFR EPI-CKD (mL/min/m2), mean (SD) 62.7 (21.2) 65.4 (23) 0.350 − 12.1
eGFR EPI-CKD stage, No. (%)
 1 20 (10.6) 45 (21.7) 0.600 − 31.1
 2 80 (42.6) 77 (37.2)
 3 76 (40.4) 71 (34.3)
 4 10 (5.3) 11 (5.3)
 5 2 (1.1) 3 (1.5)
Albuminuria (mg/day), median [IQR] 57.3 [35—158.1] 120.5 [75.8 – 223.8] 0.115 − 25.2
Haemoglobin (mg/dL), mean (SD) 13.4 (1.3) 12.9 (1.5) 0.377 36.8
Glycemia (mg/dL), mean (SD) 152.7 (49) 155.9 (43.1) 0.924 − 6.9
HbA1c (%), mean (SD) 7.3 (1.1) 7.5 (1.1) 0.345 − 18.2
HbA1c Target, No. (%) 100(53.2) 66 (31.9) 0.001 43.1
Diabetes duration, median [IQR], y 9 (6–15) 9 (7–16) 0.801 − 11.4
Cholesterol (mg/dL), mean (SD) 
 Total 185.8 (34.1) 187.6 (33.2) 0.688 − 5.5
 LDL 111.5 (30.8) 107.5 (27) 0.703 13.7
Total Cholesterol Target, No. (%) 67 (35.6) 64 (30.9) 0.475 5.6
HDL Cholesterol Target, No. (%) 99 (52.7) 75 (36.2) 0.237 14.5
LDL Cholesterol Target, No. (%) 73 (38.8) 69 (33.3) 0.911 6.2
Triglycerides (mg/dL), median (IQR) 111 (88 – 153) 148 (115 – 190) 0.063 − 42.7
Therapy
Anti-hypertensive Therapy, No. (%) 0.791 − 24.8
 1 105 (55.9) 94 (45.4)
 2 20 (10.6) 31 (15)
 3 32 (17) 44 (21.3)
 4 18 (9.6) 27 (13)
 5 13 (6.9) 11 (5.3)
ACEi/ARBs, No. (%)
 ACEi 119 (63.2) 125 (60.2) 0.748 −  25.6
 ARBs 66 (35.4) 77 (37.4)
 ACE + ARBs 3 (1.4) 5 (2.4)
Diuretics, No. (%) 83 (44.1) 113 (54.6) 0.840 − 21.0
Calcium Channel Blockers, No. (%) 63 (33.5) 82 (39.6) 0.792 − 12.7
Beta-blockers, No. (%) 31 (16.5) 38 (18.4) 0.655 − 4.9
Alpha-blockers, No. (%) 13 (6.9) 11 (5.3) 0.395 6.7
Diabetes Therapy, No. (%) 0.361 − 27.7
 Diet 16 (8.5) 5 (2.4)
 Insulin 50 (26.6) 60 (29)
 Oral anti-hyperglycemics* 97 (51.6) 108 (52.2)
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arm. Global imbalance, estimated using c-statistic, was 
around 0.8.
Intervention output
The median duration of intervention was 3.84 and 
3.40 years in MT and SoC group, respectively. At the end 
of the intervention phase period, we found a significantly 
lower level of SBP, HbA1c, total and LDL cholesterol in 
the intensive-treatment arm (Table 2).
In particular, during the Interventional Study Period, 
we observed a significant decline of BP, HbA1c and lipids 
in the MT arm already after the first year of interven-
tion, after which mean values remained almost stable; 
conversely, no significant changes were detected in SoC 
group (Fig. 2).
In MT group, achievement of BP target < 130/80 mmHg 
was significantly higher overall (68.3% vs 50.9%, p < 0.001) 
and by component (SBP 77.4% vs 55.6%, p < 0.001 – DBP 
81.9% vs 78.1%, P = 0.003) (Additional file  3: Fig. S2). 
Similarly, HbA1c, total and LDL cholesterol targets were 
achieved more frequently in the intensive-treatment arm.
In MT arm, most of patients reached ≥ 4 targets (53% 
vs 29% in SoC arm); similarly, all six planned targets were 
more frequently achieved in the intervention arm (11.1% 
vs 2.4%).
Both hyperkaliemia  (K+  > 5.5 mEq/L) and renal impair-
ment (eGFR reduction > 30% than baseline values) were 
observed more frequently in the MT arm than in SoC 
arm [19 (10%) vs. 9 (5%); P = 0.120 and 30 (16%) vs 15 
(9%), P = 0.080, respectively), likely due to more frequent 
use of dual blockade of RAS with ARBs and ACEi asso-
ciation. Nonetheless, events leading to permanent ACEi/
ARB or double block discontinuation were infrequent: 
hyperkaliemia (8; 4.1% in the MT group vs. 4; 2.1% in the 
SoC group; P = 0.558) and renal impairment (3; 1.6% in 
the MT group vs. 2; 1.2% in the SoC group; P = 1.000).
Survival analysis
During follow-up (median 13.0  years, IQR 12.4–13.3). 
262 MACEs were recorded, 146 in the SoC group 
and 116 in the intensive-therapy group (Table  3). 
Kaplan Meier analysis (Fig.  3A) showed a major dif-
ference between the two arms, with a median sur-
vival of 9.6 years (95% CI 8.6–10.7) for SoC group and 
12.5  years (95% CI 11.5–13.3) for intensive-therapy 
group. The Cox shared-frailty model confirmed this 
finding at univariate analysis (HR 0.49, 95% CI 0.35–
0.69, P < 0.001), as after multiple adjustments (adjusted 
HR 0.47, 95% CI 0.30–0.74, P = 0.001).
Secondary endpoints are reported in Table  3. All-
cause mortality occurred in 189 patients (103 in the 
SoC group and 86 in the intensive-therapy group). 
The Kaplan–Meier analysis disclosed a median sur-
vival time of 11.9  years (95% CI 10.5–13.05) for SoC 
group and 13.5 years (95% CI 13.3–15.0) for intensive-
therapy group (Fig.  3 panel B). The Cox shared-frailty 
model showed a significant difference both at univari-
ate model (HR 0.58, 95% CI 0.34–0.98, P = 0.046), and 
after adjustment for confounding variables (adjusted 
HR 0.53, 95% CI 0.29–0.93, P = 0.027). Incidence of 
MI and stroke was lower in intensive-therapy group, 
while PTCA and major amputation did not differ. These 
inter-group comparisons were unadjusted because of 
the small number of events.
As additional secondary endpoint, we also analysed 
MACEs at the end of intervention phase. Overall, 74 
MACEs were recorded, 50 in the SoC group and 24 in 
the intensive-therapy group (Table  3) with an unad-
justed HR 0.28 (95% CI 0.13–0.63; P = 0.002). Dur-
ing intervention phase, we recorded kidney failure 
(either initiation of chronic dialysis or eGFR < 15  mL/
min/1.73   m2) in 12 patients (5 in the SoC group and 7 
in the intensive-therapy group).
Table 1 (continued)
Parameter SoC (n = 188) Intervention (n = 207) p SDiff (%)
 Combined Therapy 25 (13.3) 33 (15.9)
 Missing 0 (–) 1 (0.5)
Statins, No. (%) 0.569 − 10.8
 Yes 72 (38.3) 89 (43)
 Missing 0 (–) 3 (1.4)
Antiplatelets, No. (%) 0.057 − 58.8
 Yes 71 (37.8) 126 (60.9)
 Missing 0 (–) 16 (7.7)
p-values were computed by generalized estimating equations (GEE) model with cluster as group variable
BMI Body Mass Index, BP Blood Pressure, GFR Glomerular Filtrate, HbA1c Glycated haemoglobin, IQR interquartile range, SD standard deviation, ACEi Angiotensin-
Converting-Enzyme inhibitor, ARBs Angiotensin II receptor blockers
*Metformin, Pioglitazone, acarbose, etc
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Discussion
This cluster-randomized trial demonstrates that in 
DKD patients at very high cardiovascular risk, a mul-
tifactorial intensive treatment significantly reduces the 
risk of MACEs versus SoC. This cardiovascular benefit 
becomes evident early during the three years of inter-
vention and persisted over the long-term follow-up of 
13  years. Noteworthy, the favourable effect extends to 
all-cause mortality.
Several studies have demonstrated the high cardiovas-
cular risk in T2DM. Among these, the large meta-anal-
ysis by the Emerging Risk Factors Collaboration centre 
showed a significantly higher adjusted risk among indi-
viduals with diabetes at younger ages and women, as 
Table 2 Differences in demographic, clinical and laboratory parameters and pharmacological treatment between SoC and Intensive 
therapy group at end of intervention
Data are mean (SD) or median [IQR]
P Blood Pressure, GFR Glomerular Filtration rate, HbA1c glycated haemoglobin, ACEi Angiotensin-Converting-Enzyme inhibitor, ARB Angiotensin II receptor blockers
** P values refer to difference between SoC and Intensive therapy at the end of treatment and were computed by generalized estimating equations (GEE) model with 
cluster as group and adjusted with baseline value as covariate
Parameter End of treatment
SoC Group (n = 169) Intervention group (n = 199) p**
Systolic blood pressure (mmHg) 135.1 (15.2) 127.3 (8.7) 0.004
Diastolic blood pressure (mmHg) 78.8 (8.8) 78.1 (5.6) 0.110
 BP < 130/80 mmHg (%) 132 (74.2) 163 (84.5) 0.045
Laboratory tests
eGFR EPI-CKD (mL/min) 60.7 (22.9) 60.4 (22.5) 0.920
Albuminuria (mg/day) 90.2 (38–160) 54 (11–180) 0.179
 Albuminuria < 30 mg/day (%) 18 (13.0) 62 (37.6) 0.047
Fasting plasma glucose (mg/dL) 153.6 (44.8) 147.4 (39.4) 0.199
HbA1c (%) 7.4 (1.1) 6.9 (0.6) 0.009
 HbA1c < 7% (%) 88 (52.1) 129 (64.8) 0.133
Total cholesterol (mg/dL) 190.9 (33) 173 (28.9) 0.015
Total cholesterol < 175 mg/dL (%) 55 (32.5) 106 (53.2) 0.054
LDL cholesterol (mg/dL) 122.3 (29.8) 100.5 (26.5)  < 0.001
LDL < 100 mg/dL (%) 34 (20.1) 106 (53.2) 0.001
Triglycerides (mg/dL), median (IQR) 122 (90–171) 145 (120–169) 0.794
Therapy
 Anti-hypertensive drugs, median (IQR) 1 (1–3) 2 (1–3)  < 0.001
ACEi/ARBs, No. (%)
 ACEi 104 (61.8) 7 (3.4)
 ARBs 56 (33.1) 5 (2.3)
 ACE + ARBs 3 (1.8) 187 (94.3)
 None 6 (3.6) –  < 0.001
Diuretics, No. (%) 84 (49.7) 113 (56.8) 0.864
Calcium channel Blockers, No. (%) 59 (34.9) 79 (39.7) 0.687
Beta-blockers, No. (%) 30 (17.8) 38 (19.1) 0.961
Alpha-blockers, No. (%) 6 (3.6) 10 (4.8) 0.574
Diabetes therapy, No. (%) 0.843
 Diet 5 (2.9) 5 (2.5)
 Insulin 57 (33.7) 73 (36.7)
 Oral anti-hyperglycemics 77 (45.6) 88 (44.2)
 Combined therapy 16 (9.5) 25 (12.6)
 Missing 14 (8.3) 8 (4)
Use of statins, No. (%) 84 (49.7) 110 (55.3) 0.991
Use of antiplatelets, No. (%) 104 (61.6) 148 (74.4) 0.905
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well as a strong association with cardiovascular deaths 
[23]. Likewise, in the Swedish National Diabetes Regis-
ter, a close association between CV events and the num-
ber of risk factors at goal was further disclosed [24]. This 
high residual risk is matter of debate. It may be possibly 
due to inadequate global management of risk factors. 
Indeed, the European Euro Heart Survey showed how a 
poly-pharmacological approach improved prognosis of 
patients with diabetes [25]. Nevertheless, a multi-drug 
therapy in T2DM does not guarantee for the gain of the 
different goals suggested by guidelines, as reported by the 
EUROASPIRE IV survey [26]. Such a gap between goals 
and real-life findings suggests the need of a multidiscipli-
nary approach in diabetology outpatient clinics [27–30].
Although several observational studies have confirmed 
the association between risk factors and cardiovascular 
outcome, solid evidence on the efficacy of a multifacto-
rial intervention in reducing the risk in DKD patients is 
Fig. 2 Changes in Blood Pressure, Glycemic and Lipids Control during the Interventional Study Period in the two arms of the study. A–E Mean 
(± SD) values for selected risk factors during the interventional part of the study for patients under Standard of Care (SoC) treatment (grey lines) 
and multifactorial therapy (MT) (black lines). Mean values were obtained at baseline, after 1-year, after 2-years and at end of interventional period 
(3.84 years in MT and 3.40 years in SoC). At these intervals, the total numbers of patients in both study groups were 395, 380, 372, and 368, 
respectively
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limited. Indeed, only one randomized trial (Steno-2) has 
addressed this issue.[7, 8]. Steno-2 trial randomized 160 
T2DM albuminuric patients either to an intensive mul-
tifactorial therapy or SoC. Although main therapeutic 
goals (HbA1c, lipids and BP) were not fully achieved in 
the intensive-treatment group, after a mean follow-up 
of 7.8 years, patients intensively treated had a significant 
50% lower risk of both cardiovascular and microvascular 
events [7].
To date, the findings of Steno-2 study were not con-
firmed by other studies, even in those enrolling diabetic 
subjects regardless of DKD selection criterion. In multi-
centre, open-label, randomized, J-DOIT3 study [31], type 
2 diabetes patients, not specifically selected with DKD, 
were randomly assigned to either multifactorial intensive 
or conventional therapy and followed up for a median of 
8.5 years. Notably, the study did not evidence any efficacy 
of intensified multifactorial intervention compared with 
current standard care on the prevention of a composite 
of coronary events, cerebrovascular events, and all-cause 
mortality.
Of note, the present trial was originally conceived to 
overcome the limits of the Steno-2, in terms of study 
planning (we adopted a multicentre study design) as 
well as patients’ selection. Indeed, our population was 
older (67 vs 55 yrs), well balanced for sex (in Steno-2 
men accounted for 75% study population) and with a 
lower eGFR (64 vs 117 ml/min/1.73   m2). These features 
make our population much closer to the albuminu-
ric T2DM subjects from National Registries, and thus 
more representative of real-life population with diabe-
tes [24, 32]. We originally enrolled only patients at pri-
mary cardiovascular prevention, unlike Steno-2, which 
also recruited patients with prior cardiovascular events. 
Furthermore, our cohort had DR as inclusion criterion. 
The combination of albuminuria and DR portends a 
Table 3 Clinical outcome in the two groups (n = 395)
MACE Major Adverse Cardiovascular Event
* p-value calculated with univariable Cox shared-frailty model. Multivariable estimates are reported in the manuscript
Event SoC group (n = 188) Intervention group (n = 207) p*
End of follow-up
 MACEs, No. (%) 146 (77.8) 116 (56.1)  < 0.001
 All-cause death, No. (%) 103 (54.8) 86 (41.6) 0.046
 Myocardial infarction, No. (%) 44 (23.4) 32 (15.5)  < 0.001
 Stroke, No. (%) 28 (14.9) 19 (9.2) 0.002
 Revascularization, No. (%) 13 (6.9) 16 (7.8) 0.33
 Major amputation, No. (%) 3 (1.6) 2 (0.9) 0.5
Follow-up at end of intervention phase
 MACEs, No. (%) 50 (26.6) 24 (11.6) 0.002
Fig. 3 Kaplan–Meier Estimates of the Composite Endpoint of MACEs during the whole study period (intervention and follow-up) (A) and of 
mortality during the whole study period (intervention and follow-up) (B) in the Conventional-Therapy and Intensive-Therapy Groups, respectively
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higher cardiovascular risk [33]. The higher cardiovascu-
lar risk in our study population vs Steno-2 cohort more 
likely explains the effectiveness of a shorter multifactorial 
treatment (3.84 vs. 7.8 years in Steno-2). Moreover, in our 
study, the risk reduction induced by intensive treatment 
occurred earlier than in Steno-2; indeed, frailty model 
showed a significantly lower risk for overall mortality and 
MACEs, already evident at end of intervention phase.
The pathophysiological mechanisms underlying the 
cardiovascular protective effect in MT arm can only be 
hypothesized. Besides the well-known effects of BP low-
ering treatment with RAS inhibition, the intensive gly-
caemic control with the consequent “legacy effect” on 
AGEs [33], the effect of statin on LDL and inflammatory 
cytokines [34, 35], and the inhibition of platelet adhesion, 
which reduces leukocyte infiltration and atherosclerosis 
[36], more likely, the combination of different interven-
tions may have been critical.
In our study, centres allocated to intensified therapy 
achieved a higher rate of patients at target for both single 
and multiple risk factors. Of note, the intervention study 
took place before GLP1-RA and SGLT2i had been mar-
keted in Italy. Therefore, these drugs, though character-
ized by important cardioprotective effect [1], could not 
be assessed.
In the NID-2 study, the intervention phase was com-
pleted in 2011, prior to the publication of the Veterans 
Affairs Nephropathy in Diabetes (VA-NEPHRON-D) 
study, [37] which firstly showed in diabetic nephropathic 
patients an association between the combination of 
ACEi and ARB and an increased risk either of decreased 
eGFR and/or of the onset of hyperkaliaemia. However, 
the NID-2 protocol required a strict monitoring of renal 
function and serum electrolytes and required the per-
manent withdrawal of dual RAS blockade in the case of 
persistent side effects, as above reported. Notably, during 
intervention phase the percentage of subjects who had 
to suspend treatment with drugs active on the RAS due 
to persistent side effects was low and was similar to what 
was recorded in the Altitude study [38].
Our study has several strengths. First, it is the first 
multicentre study showing the effectiveness of a mul-
tifactorial treatment on MACEs. Second, durabil-
ity of our findings was confirmed by means of a long 
follow-up. In addition, randomization by centre makes 
the study closer to real-life clinical practice. On this 
regard, it is noteworthy that the SoC arm showed a 
more favourable clinical picture at baseline in compari-
son with the intervention arm. This finding reasonably 
excludes the possibility of selecting in SoC arm those 
physicians with lower attitude to adhere to clinical 
guidelines. However, the cluster-randomized design 
has a number of limitations, such as the lack of blind 
assignment, power and precision are lower than an 
individually randomized trial and the ability to control 
for both known and unknown confounder is reduced. 
There is extensive discussion in the Literature on strat-
egies and methods to reduce these limitations and mit-
igate the impact on results. We attempted at the best 
use of them to achieve internal validity so that unbiased 
estimates of efficacy can be obtained within the study 
population and generalized to target population [39]. 
Specifically, the main results of the study were adjusted 
for both the cluster factor due to randomization and for 
the main variables resulted either unbalanced or clini-
cally and statistically associated with outcome.
As major limitation, we did not collect clinical and 
laboratory data during the follow-up occurring after 
intervention phase but only events of interest (death and 
cardiovascular events) thus precluding the possibility of 
identify a prevailing factor definitely associated with risk 
reduction. In addition, some factors possibly related to 
CV outcome, such as uric acid or proBNP [40, 41], were 
not included in our laboratory panel. Therefore, we can-
not identify one or more specific factor definitely associ-
ated with risk reduction; however, our original aim was 
to test efficacy of a global approach rather than effects of 
single interventions.
Moreover, the choice of a composite of fatal and non-
fatal MACEs as primary endpoint may explain the lack 
of a sufficient power for mortality outcome. Finally, the 
SoC population was two-years older than the intensi-
fied treatment one. However, considering the mean age 
in both groups > 65  years, the high CV risk as inclusion 
criterion, and both a higher mean DBP and a much lower 
prevalence of HbA1c target subjects at baseline in the 
intervention group, we believe the two groups are clini-
cally comparable.
Conclusions
Therefore, this multicentre trial demonstrates that a 
strategy based on intensive treatment of main risk fac-
tors is more effective than standard of care in preventing 
MACEs in type 2 DKD. Pursuing such a strategy triggers 
a marked improvement of outcomes occurring early after 
its implementation and lasting in the long-term.
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